A new rodent model to assess blood stage immunity to the plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies by de Koning-Ward, Tania F. et al.
	 	
	
 
 
This is the published version:  
 
de	Koning‐Ward,	Tania	F.,	O'Donnell,	Rebecca	A.,	Drew,	Damien	R.,	Thomson,	Russell,	Speed,	
Terence	P.	and	Crabb,	Brendan	S.	2003,	A	new	rodent	model	to	assess	blood	stage	immunity	to	the	
plasmodium	falciparum	antigen	merozoite	surface	protein	119	reveals	a	protective	role	for	
invasion	inhibitory	antibodies,	The	journal	of	experimental	medicine,	vol.	198,	no.	6,	pp.	869‐875.	
	
	
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30028155	
	
	
	
Reproduced	with	the	kind	permission	of	the	copyright	owner.		
	
Copyright	:	2003,	Rockefeller	University	Press 
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 
J. Exp. Med. 
 
©
 
 The Rockefeller University Press • 0022-1007/2003/09/869/7 $8.00
Volume 198, Number 6, September 15, 2003 869–875
http://www.jem.org/cgi/doi/10.1084/jem.20030085
 
869
 
A New Rodent Model to Assess Blood Stage Immunity to the 
 
Plasmodium falciparum
 
 Antigen Merozoite Surface Protein 1
 
19 
 
Reveals a Protective Role for Invasion Inhibitory Antibodies
 
Tania F. de Koning-Ward, Rebecca A. O’Donnell, Damien R. Drew,
 
Russell Thomson, Terence P. Speed, and Brendan S. Crabb
 
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
 
Abstract
 
Antibodies capable of inhibiting the invasion of 
 
Plasmodium
 
 merozoites into erythrocytes are present
in individuals that are clinically immune to the malaria parasite. Those targeting the 19-kD
COOH-terminal domain of the major merozoite surface protein (MSP)-1
 
19 
 
are a major
component of this inhibitory activity. However, it has been difficult to assess the overall
relevance of such antibodies to antiparasite immunity. Here we use an allelic replacement
approach to generate a rodent malaria parasite (
 
Plasmodium berghei
 
) that expresses a human
malaria (
 
Plasmodium falciparum
 
) form of MSP-1
 
19
 
. We show that mice made semi-immune to
this parasite line generate high levels of merozoite inhibitory antibodies that are specific for
 
P. falciparum
 
 MSP-1
 
19
 
. Importantly, protection from homologous blood stage challenge in
these mice correlated with levels of 
 
P. falciparum
 
 MSP-1
 
19
 
–specific inhibitory antibodies, but
not with titres of total MSP-1
 
19
 
–specific immunoglobulins. We conclude that merozoite
inhibitory antibodies generated in response to infection can play a significant role in suppressing
parasitemia in vivo
 
.
 
 This study provides a strong impetus for the development of blood stage
vaccines designed to generate invasion inhibitory antibodies and offers a new animal model to
trial 
 
P. falciparum
 
 MSP-1
 
19 
 
vaccines.
Key words: malaria • transfection • 
 
P. berghei
 
 • merozoite • invasion inhibition
 
Introduction
 
It is well established that antibodies targeting merozoite
antigens can mediate a degree of immunity to 
 
Plasmodium
falciparum
 
 malaria and this knowledge underpins the develop-
ment of blood stage vaccines against this devastating pathogen
(for review see references 1 and 2). Such antibodies are
thought to operate by a number of different mechanisms
including the prevention of merozoite release (3), the
direct neutralization of merozoites (4, 5), and the induction
of monocyte-mediated parasite killing (6). However, the
relative contribution of these different mechanisms to
controlling blood stage parasitaemia remains unclear. A
better understanding of this is particularly important for
the development of functional “correlate-of-protection”
assays for use in clinical trials of malaria vaccine candidates.
A protective role for merozoite invasion inhibitory
antibodies, which are those that act in a manner that is
independent of complement or other cellular mediators,
has been difficult to formally demonstrate and quantify.
There are several reasons for this. First, there has been a
lack of robust in vitro inhibition assays that account for
confounding factors present in serum that can cause non-
specific inhibitory, or indeed growth-promoting, effects.
Although in vitro inhibition assays have been used for some
 
time to assess antibodies to 
 
P. falciparum
 
 merozoite antigens
and have provided a useful guide as to the inhibitory activity
of a particular serum or monoclonal antibody, the problems
associated with accurate quantification of this activity,
especially in whole serum, are well recognized in the field
(4, 5, 7, 8). With respect to one important antigen, the 19-kD
COOH-terminal domain of 
 
P. falciparum
 
 merozoite surface
protein (MSP)-1
 
19
 
, this problem has now been overcome
with the development of an assay that allows accurate
quantification of MSP-1
 
19
 
–specific inhibitory antibodies in
 
Address correspondence to Brendan S. Crabb, The Walter and Eliza
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Abbreviations used in this paper:
 
 EGF, epidermal growth factor; GST,
 
glutathione 
 
S
 
-transferase; IFA, immunofluorescence assay; MSP, merozoite
surface protein; UTR, untranslated region.
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whole serum (9, 10). This assay involves a comparison of
the inhibitory effect of a given serum on two isogenic
parasite lines that differ only in MSP-1
 
19
 
. One expresses the
 
P. falciparum
 
 domain and the other expresses an antigen-
ically distinct domain from a rodent malaria parasite
 
Plasmodium chabaudi
 
. Using this assay in a previous study,
we determined that the invasion inhibitory activity of
antibodies present in serum obtained from adults that are
clinically immune to malaria, as a result of frequent ex-
posure to 
 
P. falciparum
 
, is dominated by those targeting
MSP-1
 
19 
 
(9). This finding was consistent with many
studies that had implicated a protective role for MSP-
1
 
19
 
–specific antibodies generated in response to infection
or vaccination with recombinant proteins (for review
see references 11 and 12). Despite the surprising knowl-
edge that antibodies of this single specificity make such
an important contribution to the process of invasion in-
hibition, it remained uncertain whether these antibodies
actually contribute significantly to immunity.
The major remaining obstacle to addressing the pro-
tective role of inhibitory antibodies is the lack of a sim-
ple and robust in vivo challenge system that can be used
in parallel with an in vitro inhibition test. In this paper,
we have developed such an in vivo model by generating
a rodent malaria parasite line that expresses 
 
P. falciparum
 
MSP-1
 
19 
 
in place of its own domain. Using this model,
we show that the level of MSP-1
 
19
 
–specific invasion in-
hibitory antibodies generated in mice that had been re-
peatedly exposed to this chimeric parasite line correlates
with the ability of these animals to control a subsequent
blood stage infection. The availability of this novel ro-
dent malaria model also provides an alternative to non-
human primates for assessing and monitoring 
 
P. falci-
parum
 
 MSP-1
 
19
 
–based vaccines.
 
Materials and Methods
 
Plasmids and Plasmodium berghei
 
 
 
Transfection.
 
To create pPb-
PfM19, 1.3 Kb 
 
P. berghei
 
 
 
MSP-1
 
 targeting sequence was fused in
frame to the MSP-1
 
19 
 
region of 
 
P. falciparum
 
 (see Fig. 1). PCR
was performed on 
 
P. berghei
 
 ANKA and 
 
P. falciparum
 
 D10 geno-
mic DNA (gDNA) using oligonucleotides PbF (5
 

 
-CGGGG-
TACCATCGATAAATACTTTACCTCTGAAGCTGTTCC)
and PbR1 (5
 

 
- TACATGCTTAGGGTCTATACCTAATA-
AATC), and PbPfF (5
 

 
-GGTATAGACCCTAAGCATGTAT-
GCGTAAAAAAACAATGTCCAGAA) and PfR (5
 

 
-TGCTC-
TAGATTAAATGAAACTGTATAATATTAAC), respectively,
and sewing products together via PCR using the primers PbF and
PfR. The resulting fragment was cloned into the KpnI/XbaI sites
of pGem4Z (Promega) that harbored the 
 
hsp86
 
 3
 
 
 
untranslated
region (UTR; reference 13). The 
 
MSP-1/hsp86
 
 3
 
 
 
sequence was
excised with KpnI/HindIII, the HindIII site filled in with Kle-
now reagent and the fragment cloned into the KpnI/HincII site
of pD
 
B
 
D
 
Tm
 

 
H
 
D
 
B 
 
(14). A 0.55 Kb 3
 
 
 
targeting sequence was then
cloned into the EcoRV/BamHI site of this vector to create pPb-
PfM19. The 3
 
 
 
targeting region comprising the 
 
P. berghei MSP-1
 
3
 
 
 
UTR was identified by library screen (15) and PCR amplified
from 
 
P. berghei
 
 ANKA gDNA using oligonucleotides PbM3
 

 
F
(5
 

 
-GGCGATATCATAAATTATTGAAATATTTGTTGGA)
and PbM3
 

 
R (5
 

 
-CGCGGATCCTATACAAAACATATAC-
AAC). The plasmid pPb-PbM19 is analogous to that of pPb-
PfM19 with the exception that the entire 
 
MSP-1
 
 5
 
 
 
targeting se-
quence is that of 
 
P. berghei
 
. This fragment was amplified from 
 
P.
berghei
 
 ANKA gDNA using the oligonucleotides PbF and
PbR2 (5
 

 
-TGCTCTAGATTAAAATATATTAAATACAAT-
TAATGTG). Linearized plasmids were transfected into 
 
P.
berghei
 
 ANKA parasites essentially as previously described (16,
17, 18).
 
MSP-1
 
19 
 
Glutathione S-Transferase (GST) Fusion Proteins and
Generation of Antisera.
 
The DNA sequence corresponding to
amino acids Gly 1672–Ser 1766 of 
 
P. berghei
 
 MSP-1
 
19 
 
was am-
plified using the oligonucleotides PbM19eF (5
 

 
-CGCGGATC-
CGGTATAGACCCTAAGCATGTATG) and PbM19eR (5
 

 
-
Figure 1. Schematic representation of P. berghei and P. falciparum MSP-1 chimeras. The MSP-1 sequences of P. berghei (gray), P. falciparum (red),
and P. chabaudi (blue) are represented. The arrows indicate the MSP-1 secondary cleavage site.
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GGAAGATCTTAGCTACAGAATACACCATCATAAT).
The resulting product was ligated into the BamHI site of
pGEX-4T-1 and expressed as a GST fusion protein (termed
GST-PbM19). Rabbit antisera to GST-PbM19 was derived as
previously described (9). Western blot and indirect immunoflu-
orescence assay (IFA) were performed as previously described
(9, 19, 20).
 
Generation of Semi-immune Mice.
 
Semi-immune BALB/c
mice were generated by the administration of 10
 
4 
 
erythrocytes in-
fected with either Pb-PbM19 or Pb-PfM19. At 5–10% para-
sitemia, mice were treated consecutively for 5 d with chloroquine
(10 mg/kg body weight, injected i.p.). Recrudescence was typi-
cally observed 1 wk after this primary infection, after which mice
were administered another five doses of chloroquine. 1 mo later
mice were experimentally reinfected and then drug cured as de-
scribed above. Sera were obtained from individual mice 10 d after
the final drug treatment to monitor MSP-1
 
19 
 
antibodies. For chal-
lenge infections, mice were injected i.p with 5 
 
 
 
10
 
6 
 
Pb-
PbM19– or Pb-PfM19–infected erythrocytes and the course of
parasitemia was monitored by microscopy.
 
Serology.
 
Antibodies reacting with recombinant 
 
P. berghei
 
 or
 
P. falciparum
 
 MSP-1
 
19 
 
were detected by ELISA (9). Blood taken
from mice before primary infection were used as negative con-
trols. The ELISA endpoint titres were taken as the highest serum
dilution that gave an OD reading five times above that of the
control sera. Inhibition of invasion assays were performed as pre-
viously described (9).
 
Results
 
Allelic Replacement of P. berghei MSP-1
 
19 
 
with P. falciparum
MSP-1
 
19
 
: Functional Complementation of Divergent MSP-1
 
19
 
Sequences.
 
To establish whether 
 
P. falciparum
 
 MSP-1
 
19 
 
can
complement the in vivo function of the divergent 
 
P. berghei
 
MSP-1
 
19 
 
domain, we created a 
 
P. berghei
 
 MSP-1 chimera
that expresses 
 
P. falciparum
 
 MSP-1
 
19 
 
in place of the endoge-
nous molecule (Fig. 1). The transfection vector pPb-
PfM19 was designed to integrate into 
 
P. berghei MSP-1
 
 and
replace the endogenous sequences encoding epidermal
growth factor (EGF) domains 1 and 2, and the GPI recog-
nition sequence, with the corresponding 
 
P. falciparum
 
 (D10
line) sequence (Figs. 1 and 2 A). A second plasmid, pPb-
PbM19, designed to integrate in an identical manner but
resulting in a homologous MSP-1
 
19 
 
replacement, was also
constructed to generate a control transfectant. Both plas-
mids were electroporated into the 
 
P. berghei
 
 (ANKA) line
and transgenic parasites were cloned by limiting dilution.
Southern blot analysis of gDNA showed that integration
had occurred in these parasites by the expected double
crossover event into 
 
MSP-1
 
 (Fig. 2). The resulting 
 
P.
berghei
 
/
 
P. falciparum
 
 chimeric line, which we have termed
Pb-PfM19, could be distinguished from a control 
 
P. berghei
transfection line, termed Pb-PbM19, by digestion with PstI
Figure 2. Generation of P. berghei chimera lines
containing either P. berghei or P. falciparum MSP-119.
(A) Schematic diagram of the P. berghei MSP-1 locus,
the transfection vector (pPb-PfM19) used to replace
the endogenous MSP-119 molecule, and the predicted
MSP-1 locus of the Pb-PfM19 chimeric line after
integration. The gray box represents endogenous P.
berghei MSP-119 sequence and the black box represents
P. falciparum MSP-119 sequence (or P. berghei MSP-119
sequence for creation of the Pb-PbM19 chimeric line).
The solid lines in pPb-PfM19 depict targeting sequence.
TgDHFR-TS, selectable marker cassette; 3, HSP86 3
UTR. The expected sizes of fragments resulting from
digestion with either HincII (H) or PstI (P) are shown.
(B) Southern blot analysis of digested genomic DNA
from P. berghei wild-type and chimeric lines.
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(Fig. 2 B). In addition, PCR amplification of gDNA using
oligonucleotides specific for the integration events con-
firmed the expected integration event (unpublished data).
To determine whether the Pb-PfM19 and Pb-PbM19
lines expressed the expected MSP-119 domains, Western
blot analysis was performed on late stage parasite extracts
using specific anti–MSP-119 antibodies (Fig. 3 A). P. falci-
parum MSP-119 antibodies recognized both MSP-119 and
an 200-kD band corresponding to full-length MSP-1 in
Pb-PfM19 parasites but not in Pb-PbM19 parasites. In
contrast, antibodies specific for P. berghei MSP-119 only
recognized MSP-119 and full-length MSP-1 in wild-type
P. berghei and the transfection control line, Pb-PbM19.
This demonstrates that P. falciparum MSP-119 can be cor-
rectly expressed and processed in P. berghei and that the
endogenous MSP-119 gene is no longer expressed in Pb-
PfM19 parasites. The localization of MSP-119 in P. berghei
lines was also assessed by double-labeling IFA. Character-
istic merozoite surface labeling was observed in both chi-
mera lines, with Pb-PfM19 parasites reacting only with
the P. falciparum–specific monoclonal antibody 4H9/19,
whereas P. berghei wild-type and Pb-PbM19 chimeric par-
asites reacted only with rabbit anti–P. berghei MSP-119
antibodies (Fig. 3 B). This confirms that the appropriate
MSP-119 domain is correctly localized in both Pb-PbM19
and Pb-PfM19 parasite lines. The growth rates of the
transfected lines were also examined and compared with
the wild-type parasite line (Fig. 3 C). All mice injected
with 104 parasites succumbed to infection over a similar
time frame, regardless of which parasite line they were
given. These results extend our previous finding that the
function of MSP-119 during in vitro culture is conserved
across divergent Plasmodium species (9, 20) to show that
MSP-119 function is also conserved during the erythro-
cytic cycle in vivo.
A Key Role for MSP-119–specific Invasion Inhibitory Anti-
bodies in Protection Elicited by Repeated Infection/Drug Cure.
Sera from BALB/c mice that were rendered semi-immune
to either Pb-PfM19 or Pb-PbM19 as a result of a low dose
infection/drug cure regimen were tested for total MSP-119
Figure 3. Phenotypic analysis of P. berghei chimeric lines. (A) Western blot analysis of late stage parasite extracts using rabbit PbM19 or PfM19
antibodies (both diluted 1/4,000) detecting both full-length MSP-1 (200 kD) and MSP-119 (19 kD). (B) Localization of MSP-119 by IFA. Schizont
stage parasites were incubated with a mixture of rabbit PbM19 (1/1,000) and 4H9/19 (PfM19; 1/100) antibodies, followed by a mixture of FITC-
conjugated anti–rabbit and rhodamine-conjugated anti–mouse immunoglobulins (both diluted 1/200). (C) Course of blood parasitemia in mice after
infection at day 0 with P. berghei wild-type, Pb-PbM19, or Pb-PfM19. Shown is the mean  SD of the parasitemia observed in five mice.
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antibodies in ELISA and for MSP-119–specific invasion in-
hibitory antibodies. Using MSP-119 GST fusion proteins as
antigen in an ELISA, all mice generated a strong MSP-119
antibody response that was specific for the relevant MSP-119
domain (Fig. 4 A). This data highlights the immunogenicity
of this domain in the context of a low dose blood stage in-
fection procedure and validates the expression of the appro-
priate MSP-119 domains in the transfected P. berghei lines.
For the in vitro inhibition assay, the ability of a given serum
to inhibit the invasion of RBC by two isogenic P. falciparum
lines, D10-PfM3 and D10-PcMEGF (Fig. 1), was compared.
D10-PcMEGF expresses the antigenically diverse P. chabaudi
MSP-119 polypeptide and so is not recognized by P. falciparum
MSP-119–specific antibodies. This line was used as an alter-
native to a P. falciparum chimera expressing P. berghei MSP-
119 because the latter is currently not available. Hence, P.
falciparum MSP-119–specific invasion inhibitory activity of a
given serum can be calculated by determining the difference
in invasion rates of D10-PfM3, which uses the wild-type P.
falciparum MSP-119 domain for invasion, and D10-PcMEGF in
the presence of the test serum. All sera from Pb-PfM19 mice
inhibited D10-PfM3 parasites far more effectively than D10-
PcMEGF parasites (Fig. 4 B). Conversely, all sera from Pb-
PbM19 immune mice inhibited D10-PcMEGF more effec-
tively than wild-type P. falciparum. Because P. chabaudi and P.
berghei are closely related rodent parasites with somewhat con-
served MSP-119 domains (73% identity), a degree of antigenic
cross-reactivity was expected here. However, because many
epitopes differ between the MSP-119 domains of rodent ma-
laria parasites (21), the invasion inhibitory activity of these sera
cannot be accurately determined.
To determine if there is an association between the lev-
els of MSP-119–specific invasion inhibitory antibodies
present in mouse serum and degree of protection from a
subsequent parasite challenge, Pb-PfM19 semi-immune
mice were administered a high dose (5  106) of Pb-
PfM19–infected erythrocytes 3 d after they had been bled
for the serological analyses. After challenge, the course of
parasitemia was determined and plotted against levels of
P. falciparum MSP-119–specific invasion inhibitory anti-
bodies (Fig. 5). Strong evidence of regression was ob-
served (R2  0.63; P  0.01 by ANOVA), implicating a
substantial role for MSP-119–specific inhibitory antibodies
in controlling a blood stage infection. A similarly signifi-
cant regression curve was evident when invasion inhibi-
tion was plotted against cumulative parasitemia in these
mice (R2  0.56; P  0.02). The apparent linear relation-
ship shown in Fig. 5 might be explained by the fact that
P. berghei growth in BALB/c mice in our hands has two
periods of almost log phase expansion (see Fig. 3 C). We
also performed a two-sided rank correlation test, a more
stringent analysis that does not assume a linear relationship
between two parameters. This analysis also demonstrated
significance for peak parasitemia versus MSP-119–specific
invasion inhibition (P  0.05). Importantly, all mice had
very similar anti–PfMSP-119 ELISA antibody endpoint ti-
tres when measured against MSP-119 GST fusion proteins
(Fig. 4 A) or a baculovirus-expressed P. falciparum MSP-
142 antigen (MAD20 allele). The latter antigen is likely to
represent MSP-119 in a more appropriate conformation
and the reciprocal endpoint titres obtained in this case
ranged from 104.5–105 for Pb-PfM19 mice and 102 for
Figure 4. Mice repeatedly infected with P. berghei
transfectants elicit MSP-119–specific inhibitory antibodies.
(A) Reciprocal anti–MSP-119 antibody endpoint titres of
serum from Pb-PfM19 and Pb-PbM19 immune mice against
recombinant P. falciparum and P. berghei MSP-119–GST fusion
proteins. (B) Invasion inhibition assay of D10-PfM3 and
D10-PcMEGF parasite lines in the presence of individual
serum from Pb-PfM19 and Pb-PbM19 immune mice.
Invasion is expressed as a percentage of the invasion observed
in parasites cultured in human nonimmune sera (HNIS). The
numbers shown represent the P. falciparum MSP-119–specific
invasion inhibitory activity of a given serum, calculated
by subtracting the invasion rate of D10-PfM3 from that
of D10-PcMEGF.
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Pb-PbM19 mice. Hence, no association between IgG lev-
els and protection were observed.
To assess the overall contribution of MSP-119 to blood
stage immunity, in parallel with the homologous challenge
experiment described above, groups of Pb-PbM19 and Pb-
PfM19 immune mice were cross-challenged with the het-
erologous line. In both cases the data suggested that the
groups challenged with the homologous parasite line were
better protected. When homologous and heterologous
challenge groups were combined for analysis, a difference
was observed for mean peak parasitemia (14.8% in the ho-
mologous groups compared with 18.8% in the heterolo-
gous groups), cumulative parasitemia (586% compared
with 1,033%), and time until parasite clearance (	0.01%;
12.6 compared with 15.1 d). However, although this trend
was consistent across all parameters measured, only the lat-
ter approached statistical significance (P  0.056 using log-
rank test). Thus, to further explore the overall importance
of MSP-119 antibodies to immunity, sera from P. berghei
immune mice was pooled and transferred into two groups
of five BALB/c mice (150 
l serum/mouse on days 1
and 0), which were subsequently challenged (on day 0)
with 104 Pb-PbM19 or Pb-PfM19 parasites. Mice chal-
lenged with the homologous line were significantly better
protected than those challenged with Pb-PfM19 when
comparing the parasitemia of the mice in the two groups
over the first 10 d after challenge (P  0.05 using a one-
sided permutation test) or when comparing the time taken
to reach 2% parasitemia (P 	 0.05 by log-rank test). To-
gether, these data are consistent with a significant role for
MSP-119 antibodies in the control of blood stage parasites.
Discussion
Although antibodies directed against merozoite antigens
are known targets of protective immunity, the relative im-
portance of such antibodies to clinical immunity and their
mode of action remain uncertain. In this paper we provide
strong evidence implicating a key role for merozoite inva-
sion inhibitory antibodies in reducing the parasite burden
in animals previously exposed to blood stage parasites. In
addition, consistent with our previous findings (9), we
demonstrate that antibodies that are specific for the EGF
domains of MSP-119 comprise a large component of the in-
hibitory activity of the sera from these animals.
This study involved the generation of a P. berghei parasite
line (Pb-PfM19) that expresses the P. falciparum MSP-119
domain in place of its own domain and an experiment that
demonstrates that the in vivo function of MSP-119 is fully
conserved across distantly related Plasmodium species. It is
now clear that the extensive amino acid differences be-
tween rodent and human (P. falciparum) malaria MSP-119
domains, including an absent disulfide bond in the first
EGF domain of the rodent malaria form, are not involved
in species-specific erythrocyte invasion events either in
vivo (this study) or in vitro (9, 20).
Our observation that the level of inhibitory antibodies
specific for MSP-119 correlates with the control of para-
sitaemia upon subsequent blood stage challenge has a num-
ber of important implications. First, the dominant protec-
tive role for antibodies of this single specificity provides
strong support for the development of MSP-119–based vac-
cines. Second, our findings validate the quantification of
MSP-119–specific inhibitory antibodies as a useful corre-
late-of-protection assay. It should be stressed that the mea-
surement of total MSP-119–specific immunoglobulins is not
particularly useful in this regard as some B cell epitopes
formed by this protein are not protective (7, 22) and indeed
we found no correlation between IgG levels and either in-
vasion inhibition or protection.
The model developed here may prove to be a useful tool
to test and monitor the potency of P. falciparum MSP-119–
based vaccines. At present there are numerous candidate vac-
cines based on this domain that are undergoing preclinical
testing including different recombinant forms, conformers,
and vaccine combinations that incorporate MSP-119 as one
component. MSP-142, a protein that incorporates MSP-119
and MSP-133, is the most advanced of these candidates. It ap-
pears that the protective antibodies elicited by MSP-142 are
directed against the MSP-119 fragment (the MSP-133 frag-
ment may contain T cell epitopes) and hence the animal
model developed here should be useful to analyze this vac-
cine. Currently, the only P. falciparum challenge model avail-
able to test MSP-119 antigens involves the use of nonhuman
primates. Although vaccine testing in these animals is proba-
bly an important precursor to human trials, it is clearly sub-
stantially less practical for routine efficacy testing than the
simple rodent challenge model described here.
We thank Drs. Chris Janse and Andy Waters for helpful advice on
P. berghei transfection and for provision of the P. berghei cloning
plasmid, Drs. Carole Long, Anthony Stowers, and Louis Miller for
the baculovirus-expressed MSP-142 antigen, and Drs. Louis Scho-
field and Diana Hanson for helpful discussion. We also acknowl-
edge the expert technical services provided by Lynn Buckingham.
We are grateful to the Australian Red Cross Blood Bank for the
provision of human blood and serum.
Figure 5. Evidence that MSP-119–specific inhibitory antibodies control
a blood stage infection. MSP-119–specific invasion inhibitory activity of
serum from individual Pb-PfM19 immune mice plotted against peak
parasitemia attained after challenging corresponding mice with Pb-PfM19.
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